Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
IPO Year:
Exchange: NYSE
Website: baxter.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2025 | $42.00 | Buy | Goldman |
| 2/24/2025 | Hold → Buy | Argus | |
| 2/20/2025 | $39.00 | Overweight | Barclays |
| 7/15/2024 | $39.00 → $30.00 | Equal-Weight → Underweight | Morgan Stanley |
| 5/30/2024 | $36.00 | Neutral | Goldman |
| 5/10/2024 | $40.00 | Buy → Hold | TD Cowen |
| 5/30/2023 | $45.00 | Equal-Weight | Morgan Stanley |
| 3/29/2023 | $43.00 | Neutral | UBS |
| 1/6/2023 | $55.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/5/2023 | Outperform → Mkt Perform | Raymond James |
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on July 1, 2025, to stockholders of record as of May 30, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovat
First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company's previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company's previously issued guidance Baxter increases bottom end of previous range for full-year 2025 adjusted diluted EPS guidance and now expects adjusted diluted EPS of $2.47 to $2.551 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. "Our solid performance in the first quarter of
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:40 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Sunday, November 9, 2025. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2025 financial results on Thursday, May 1, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I763359 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on B
Hemopatch Sealing Hemostat with room temperature storage now available in Europe New product evolution enables direct accessibility in the operating room Innovation is a direct result of collaborative efforts with surgeons, helping to ensure that customer needs are met and promoting enhanced patient care Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of Hemopatch Sealing Hemostat with room temperature storage at a symposium in Austria. The evolution of the product optimizes accessibility in the operating room, delivering an immediate solution for surgeons to control bleeding or prevent leakage. The product is n
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2025 Annual Meeting) in a virtual format on Tuesday, May 6, 2025 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2025 Annual Meeting. Online access to the 2025 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2025 Annual Meeting in person. The virtual format provides a safe, convenient and cost-effective experience to all stockholders regardless of location. As always, whether or not a stockholder plans to attend the virtual 2025 Annual Meeting, all stockholders of record are encouraged to vote their shar
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of
Baxter's first voice-activated technology is designed to enable care at the speed of voice Engineered to integrate with Baxter's existing connected care portfolio Designed to reduce the burden on care teams, enhance IT and operational efficiency, and support safety through streamlined communication and workflow activation Baxter International Inc. (NYSE:BAX), a global medtech leader, today unveiled Voalte Linq device powered by Scotty assistant, the company's first voice-activated technology, at the 2025 HIMSS Global Healthcare Conference. Voalte Linq, a lightweight, wearable badge, is powered by Scotty assistant, a voice-activated technology, to better enable efficient, streamlin
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Monday, September 8, 2025. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 ye
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
Goldman resumed coverage of Baxter with a rating of Buy and set a new price target of $42.00
Argus upgraded Baxter from Hold to Buy
Barclays resumed coverage of Baxter with a rating of Overweight and set a new price target of $39.00
Morgan Stanley downgraded Baxter from Equal-Weight to Underweight and set a new price target of $30.00 from $39.00 previously
Goldman initiated coverage of Baxter with a rating of Neutral and set a new price target of $36.00
TD Cowen downgraded Baxter from Buy to Hold and set a new price target of $40.00
Morgan Stanley resumed coverage of Baxter with a rating of Equal-Weight and set a new price target of $45.00
UBS initiated coverage of Baxter with a rating of Neutral and set a new price target of $43.00
Morgan Stanley downgraded Baxter from Overweight to Equal-Weight and set a new price target of $55.00
Raymond James downgraded Baxter from Outperform to Mkt Perform
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of
Addition of Mr. Craig complements current board expertise with deep financial, broad operational and public company board experience Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter's Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12. "We are excited to welcome Jay to Baxter's board," said José (Joe) E. Almeida, chair, president and CEO. "As a former CEO, CFO, COO and public company auditor, Jay's broad-based busin
Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Joel Grade as executive vice president and chief financial officer (CFO), reporting to Baxter chairman, president and CEO, José (Joe) E. Almeida, effective Oct. 18, 2023. At that time, Brian Stevens, who has served as the company's interim CFO since May 31, 2023, will transition to his prior role as senior vice president, chief accounting officer and controller. "Joel is a seasoned global financial executive with decades of deep operational and broad business experience as well as a proven record of results-driven impact," said Mr. Almeida. "I am confident we will benefit from Joel's leadership
Addition of Mr. Ampofo complements and expands current board expertise, reflects focus on continued board refreshment efforts Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed William A. Ampofo II, chair, Supply Chain Operations Council and vice president, Parts & Distribution Services and Supply Chain, Boeing Global Services, to its board of directors. Mr. Ampofo will serve on Baxter's Quality, Compliance & Technology Committee. His appointment is effective today and brings the total number of directors serving the company to 11. "William's deep operational expertise, track record as a supply chain leader, and distinguished career driving t
A proven industry leader and executive, Ryan Fernan, will help ORHub advance Ortho-Spine technology beyond current limitations.IRVINE, CA / ACCESSWIRE / July 27, 2022 / ORHub, Inc. (OTC:ORHB) officially kicks off the acquisition of PUR Biologics ("PUR") with the appointment of Ryan Fernan as the Head of PUR Biologics. An ORHub biotech company, PUR Biologics is focused on delivering next generation regenerative biologic products to address degenerative musculoskeletal diseases.Mr. Fernan, brings direct access to a broad industry network with a proven track record of over 18 years in the medical device and biotechnology industry. Recognized as a frontrunner in sales and product development, Mr
CHICAGO, March 15, 2022 (GLOBE NEWSWIRE) -- Fast Radius, Inc. (NASDAQ:FSRD), a cloud manufacturing company, today announced it has named Erin Stone as General Counsel and Corporate Secretary, and James Erkenswick as Chief Accounting Officer. These leadership additions mark important milestones for Fast Radius' evolution as a publicly traded company. In her capacity as General Counsel and Corporate Secretary, Stone will serve as an important strategic and legal advisor to Fast Radius's board of directors and management and will oversee all legal and compliance matters for the company. In his role as Chief Accounting Officer, Erkenswick will have leadership over the preparation of all financ
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks Inc., to its board of directors. Dr. Wilkes will serve on Baxter’s Quality, Compliance and Technology Committee. Additionally, Baxter has appointed Albert P.L. Stroucken, former executive chairman and chief executive officer, Owens-Illinois, Inc., and a Baxter director since 2004, as its lead independent director. Mr. Stroucken, who previously served as the chairman of the Audit Committee, wi
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
DEFA14A - BAXTER INTERNATIONAL INC (0000010456) (Filer)
DEF 14A - BAXTER INTERNATIONAL INC (0000010456) (Filer)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
EFFECT - BAXTER INTERNATIONAL INC (0000010456) (Filer)
S-3ASR - BAXTER INTERNATIONAL INC (0000010456) (Filer)
POS AM - BAXTER INTERNATIONAL INC (0000010456) (Filer)
10-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on July 1, 2025, to stockholders of record as of May 30, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovat
First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company's previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company's previously issued guidance Baxter increases bottom end of previous range for full-year 2025 adjusted diluted EPS guidance and now expects adjusted diluted EPS of $2.47 to $2.551 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. "Our solid performance in the first quarter of
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2025 financial results on Thursday, May 1, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I763359 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on B
Fourth-quarter sales from continuing operations of $2.75 billion increased 1% on a reported basis and 2% on a constant currency basis, exceeding the company's previously issued guidance1 Fourth-quarter U.S. GAAP2 diluted earnings per share (EPS) (loss) from continuing operations of ($0.95); adjusted diluted EPS from continuing operations of $0.58, exceeding the company's previously issued guidance Full-year sales from continuing operations of $10.64 billion increased 3% on both a reported and constant currency basis, exceeding the company's previously issued guidance Full-year U.S. GAAP diluted EPS (loss) from continuing operations of ($0.64); adjusted diluted EPS from continuing ope
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on April 1, 2025, to stockholders of record as of Feb. 28, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where inn
José (Joe) E. Almeida to retire as Chair, President and Chief Executive Officer Lead Independent Director Brent Shafer appointed Chair and Interim CEO Board has initiated a comprehensive search to select full-time replacement Heather Knight appointed Chief Operating Officer Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that José (Joe) E. Almeida, chair, president and chief executive officer (CEO), will retire from his executive roles with the company, effective immediately. He will serve in an advisory capacity through Oct. 31, 2025. The Baxter Board of Directors has appointed lead independent director Brent Shafer as chair and interim CEO and
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I2823858 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's lea
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock. This dividend represents the new quarterly dividend rate for Baxter in anticipation of the divestiture of its Kidney Care business segment to Carlyle (NASDAQ:CG), which is expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. Over its 93-year history, Baxter has co
Baxter third-quarter 2024 sales totaled $3.85 billion1 Third-quarter total Baxter U.S. GAAP2 diluted earnings per share (EPS) were $0.271; adjusted total Baxter diluted EPS were $0.801, exceeding the company's previously issued guidance Third-quarter sales from continuing operations of $2.70 billion increased 4% on both a reported and constant currency basis3, reflecting growth across all segments4 Third-quarter U.S. GAAP diluted EPS from continuing operations were $0.12; adjusted continuing operations EPS were $0.49 Baxter continues to make significant progress restoring production at its North Cove facility following the unprecedented impact of Hurricane Helene in western North C
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/391655054 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading portf